Syncell Welcomes New Management Team Members, Philippe Lyko and Nikhil Rao

TAIPEI, Taiwan & WATERTOWN, Mass.--(BUSINESS WIRE)--Syncell, a leader in next-generation spatial proteomics, is pleased to announce the addition of Philippe C. Lyko as Chief Financial Officer (CFO) and Nikhil Rao, PhD, as Senior Vice President of Commercial. These appointments strengthen Syncell's leadership team as the company enters a pivotal phase of growth and commercial expansion.

Philippe Lyko joins Syncell following a successful tenure at DNA Script, a pioneer in Enzymatic DNA Synthesis technology, where he held the reins as CFO for three years. Lyko brings a wealth of financial expertise, accumulated over 27 years across various industries, including significant roles in the life sciences sector. His experience also includes critical financial leadership positions at Helix, Illumina, and Flexport, where he played a key role in scaling finance operations during periods of rapid growth. Lyko’s diverse background and strategic financial acumen make him a valuable addition to Syncell as it launches the Microscoop^® platform, aiming to revolutionize proteomic discovery.

Nikhil Rao, PhD, joins Syncell as Senior Vice President of Commercial. Rao brings a distinguished career in the life sciences, particularly in the areas of spatial biology and multiomics. He most recently served as Vice President of the Spatial Business Unit at 10x Genomics, where he was instrumental in launching the Visium and Xenium platforms, significantly driving the company’s revenue. His expertise in product management and market strategy will be crucial as Syncell expands its innovative offerings in spatial proteomics. Rao holds a PhD in Bioengineering from UC San Diego and a B.S. in Chemical & Biomolecular Engineering from The Johns Hopkins University.

“We are thrilled to welcome Philippe and Nikhil to the Syncell team,” said Jung-Chi Liao, founder and CEO of Syncell. “Their extensive experience and leadership will be invaluable as we accelerate our mission to advance proteomic technologies and drive the commercial success of our groundbreaking Microscoop^® platform.”